<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006054</url>
  </required_header>
  <id_info>
    <org_study_id>199/15104</org_study_id>
    <secondary_id>UMN-MT-1995-26</secondary_id>
    <secondary_id>UMN-MT-9526</secondary_id>
    <nct_id>NCT00006054</nct_id>
  </id_info>
  <brief_title>Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fairview University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation
      for patients with primary immunodeficiencies.

      II. Determine relevant outcomes of this treatment in these patients including quality of
      survival, extent of morbidity and mortality from complications of the treatment (e.g., graft
      versus host disease, regimen related toxicities, B- cell lymphoproliferative disease), and
      completeness of functional immunoreconstitution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients with severe combined immunodeficiency (SCID) using a matched
      sibling donor receive allogeneic bone marrow or umbilical cord blood transplantation on day
      0. Patients receive graft versus host disease (GVHD) prophylaxis with methotrexate IV on days
      1, 3, 6, and 11 and cyclosporine IV on days -3 to 50.

      Patients with SCID using donors other than histocompatible siblings, Wiskott Aldrich syndrome
      using a histocompatible sibling donor, Wiskott Aldrich syndrome and under 5 years of age
      using donors other than histocompatible siblings, X-linked CD40 ligand deficiency using a
      histocompatible sibling donor, X-linked CD40 ligand deficiency and under 5 years of age using
      donors other than histocompatible siblings, other primary immunodeficiencies without
      manifestations of hemophagocytosis using a histocompatible sibling donor, or other primary
      immunodeficiencies without manifestations of hemophagocytosis and under 5 years of age using
      donors other than histocompatible siblings receive busulfan IV over 2 hours every 6 hours on
      days -9 to -6, cyclophosphamide IV on days -5 to -2, and antithymocyte globulin (ATG) twice
      daily on days -4 to -1. Allogeneic bone marrow or umbilical cord blood transplantation takes
      place on day 0. Patients receive graft versus host disease (GVHD) prophylaxis with
      methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV on days -3 to 50.

      Patients with hemophagocytic lymphohistiocytosis, Chediak Higashi syndrome, X-linked
      lymphoproliferative syndrome, severe progressive Langerhans cell histiocytosis, or other
      primary immunodeficiencies with complications of hemophagocytosis receive busulfan IV over 2
      hours every 6 hours on days -9 to -6, cyclophosphamide IV over 2 hours on days -5 to -2,
      etoposide IV over 22 hours on days -5 to -3, and ATG IV twice daily on days -2, -1, 1, and 2.
      Allogeneic bone marrow or umbilical cord blood transplantation takes place on day 0. Patients
      receive graft versus host disease (GVHD) prophylaxis with methotrexate IV on days 1, 3, 6,
      and 11 and cyclosporine IV on days -3 to 50.

      Patients with Wiskott Aldrich syndrome or other primary immunodeficiencies without
      manifestations of hemophagocytosis, who are over 5 years of age and using donors other than
      histocompatible siblings, receive busulfan IV over 2 hours every 6 hours on days -6 and -5,
      cyclophosphamide IV over 2 hours on days -4 and -3, total body irradiation on day -2, and ATG
      IV over 2 hours twice daily on days -2, -1, 2, and 3. Allogeneic bone marrow or umbilical
      cord blood transplantation takes place on days 0 and 1. Patients receive GVHD prophylaxis
      with methylprednisolone IV every 12 hours on days 2-21, oral prednisone every 12 hours on
      days 22-100 and then tapered off over days 101 to 128, and cyclosporine IV over 2 hours every
      8-12 hours on days -3 to 100.

      All patients are followed as determined by their primary physician.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Immunologic Deficiency Syndromes</condition>
  <condition>Chediak-Higashi Syndrome</condition>
  <condition>Common Variable Immunodeficiency</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>X-Linked Lymphoproliferative Syndrome</condition>
  <condition>Familial Erythrophagocytic Lymphohistiocytosis</condition>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <condition>X-linked Agammaglobulinemia</condition>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <condition>Chronic Granulomatous Disease</condition>
  <condition>X-linked Hyper IgM Syndrome</condition>
  <condition>Severe Combined Immunodeficiency</condition>
  <condition>Leukocyte Adhesion Deficiency Syndrome</condition>
  <condition>Virus-Associated Hemophagocytic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Severe combined immunodeficiency All ages with histocompatible sibling donors or with
             other donors OR Wiskott Aldrich syndrome All ages with histocompatible sibling donors
             or with other donors OR X-linked CD40 ligand deficiency All ages with histocompatible
             sibling donors OR Under 5 years of age with donors other than histocompatible siblings
             OR Other primary immunodeficiencies without manifestations of hemophagocytosis All
             ages with histocompatible sibling donors or with other donors OR Hemophagocytic
             lymphohistiocytosis (HLH) Familial erythrophagocytic lymphohistiocytosis (FEL),
             familial HLH (FHLH), recurrent virus-associated hemophagocytic syndrome (VAHS) All
             ages with related or unrelated donors OR Chediak Higashi syndrome All ages with
             related or unrelated donors OR X-linked lymphoproliferative syndrome All ages with
             related or unrelated donors OR Other primary immunodeficiencies with complication of
             hemophagocytosis All ages with related or unrelated donors OR Severe progressive
             Langerhans cell histiocytosis All ages with related or unrelated donors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. Scott Baker</last_name>
    <role>Study Chair</role>
    <affiliation>Fairview University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairview University Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>July 5, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2000</study_first_posted>
  <last_update_submitted>October 14, 2009</last_update_submitted>
  <last_update_submitted_qc>October 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2009</last_update_posted>
  <keyword>Chediak-Higashi syndrome</keyword>
  <keyword>Langerhans cell histiocytosis</keyword>
  <keyword>Wiskott-Aldrich syndrome</keyword>
  <keyword>X-linked agammaglobulinemia</keyword>
  <keyword>X-linked hyper IgM syndrome</keyword>
  <keyword>X-linked lymphoproliferative syndrome</keyword>
  <keyword>chronic granulomatous disease</keyword>
  <keyword>common variable immunodeficiency</keyword>
  <keyword>complement deficiency</keyword>
  <keyword>disease-related problem/condition</keyword>
  <keyword>familial erythrophagocytic lymphohistiocytosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>hemophagocytic lymphohistiocytosis</keyword>
  <keyword>histiocytosis</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>leukocyte adhesion deficiency syndrome</keyword>
  <keyword>primary immunodeficiency disease</keyword>
  <keyword>rare disease</keyword>
  <keyword>severe combined immunodeficiency</keyword>
  <keyword>virus-associated hemophagocytic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>Chediak-Higashi Syndrome</mesh_term>
    <mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Hyper-IgM Immunodeficiency Syndrome, Type 1</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Leukocyte-Adhesion Deficiency Syndrome</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

